ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,653 | -72.8% | 411 | -64.8% | 0.00% | -80.0% |
| Q2 2023 | $53,834 | +0.9% | 1,167 | -12.3% | 0.01% | -16.7% |
| Q1 2023 | $53,333 | +24.6% | 1,330 | +43.9% | 0.01% | +20.0% |
| Q4 2022 | $42,809 | +137.8% | 924 | +111.4% | 0.01% | +150.0% |
| Q3 2022 | $18,000 | +80.0% | 437 | +155.6% | 0.00% | +100.0% |
| Q2 2022 | $10,000 | +900.0% | 171 | +677.3% | 0.00% | – |
| Q1 2022 | $1,000 | -80.0% | 22 | -62.7% | 0.00% | -100.0% |
| Q4 2021 | $5,000 | +150.0% | 59 | +136.0% | 0.00% | – |
| Q3 2021 | $2,000 | – | 25 | +733.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 3 | -94.7% | 0.00% | -100.0% |
| Q1 2021 | $6,000 | – | 57 | +1325.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 4 | -97.1% | 0.00% | -100.0% |
| Q3 2019 | $5,000 | 0.0% | 136 | +44.7% | 0.00% | -66.7% |
| Q1 2016 | $5,000 | -16.7% | 94 | +70.9% | 0.00% | -25.0% |
| Q4 2015 | $6,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |